ARVN - Arvinas Profit before interest, taxes and amortization

Graphic logo of Arvinas Inc (ARVN)

Arvinas, Inc. relies on highly qualified management and transparent collaboration with Pfizer in the field of protein degradation. Business viability is based on the success of clinical trials and the inflow of external capital, while environmental policy is limited by bio-waste disposal regulations. The absolute cash result of operations confirms these data, and its current mark is 0.00.

Arvinas Corp (ARVN) - Operating profit EBITDA from 11/23/2025 to 11/13/2026

Arvinas - analytical breakdowns and key metrics (ARVN)

- current quotes and average value forecast:
Stock Quotes Arvinas Bio|ARVN - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Arvinas|ARVN - Total Company Value
- book capitalization data:
Equity per Share Arvinas|ARVN - Book Capitalization|Market Capitalization to Book Value Ratio arvinas.com|ARVN - Aggregate Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Arvinas, Inc.|ARVN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Arvinas Inc|ARVN - Company Aggregate Debts|Debts to Net Assets Arvinas|ARVN - Company Long-Term Debt|Company Short-Term Indebtedness Arvinas|Quick Ratio arvinas.com
- earnings and valuation multiples indicators:
ARVN - Company Net Income|Company Profit Forecast Arvinas, Inc.|ARVN - Price to Earnings Ratio|Future Price to Earnings Multiple arvinas.com|ARVN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Arvinas|ARVN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Arvinas|ARVN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months arvinas.com|ARVN - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Arvinas, Inc.
Summary company analytics:ARVN Arvinas Bio
Brand item of Arvinas Inc

Absolute operating profit measures the cash flow from core operations before depreciation, determining the business's real margin of safety. Comparing current values with historical trends allows for the identification of cyclicality and prevents overpaying for an asset. For Arvinas, Inc. (ARVN), this metric reflects the scaling efficiency of PROTAC programs supported by pharmaceutical partners. By analyzing the absolute EBITDA volume, an investor can see the dynamics of operating expense coverage. This metric is critical for assessing the company's stability during its clinical growth phase.